ArticleScience advances2024
SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition.
Abstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Salvianolic Acid A Induces Ferroptosis in Non-Small Cell Lung Cancer via the SRC/YAP/GPX4 Axis.International journal of molecular sciences · 2026Article
- Article
- ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.Science advances · 2026Article
- Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions.Research square · 2026Article
- Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition.Cell death and differentiation · 2026Article
- From Pyroptosis Heterogeneity to an Interpretable Prognostic Signature for Risk Stratification and Therapy Insights in Pancreatic Adenocarcinoma.Biomedicines · 2026Article
- Modulation of Oncogenic KRAS Signaling by Branched Actin-driven Cell Membrane Protrusions.bioRxiv : the preprint server for biology · 2026Article
- High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASNPJ precision oncology · 2026Article
- Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line.Scientific reports · 2026Article
- Targeting macropinocytosis for cancer therapy.Nature reviews. Cancer · 2026Review
- CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability.Journal of pharmaceutical analysis · 2026Review
- KRAS Inhibition in Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2026Review
- Lung cancer organoids for functional precision oncology: from disease modeling to clinical decision support.Frontiers in oncology · 2026Review
- Analysis of the SH3-Domain Kinase Binding Protein 1 Predictive Model for Pancreatic Ductal Adenocarcinoma and CCCTC-Binding Factor Transcriptional Regulatory Study.World journal of oncology · 2025Article
- The Level of a Short Form of Multidrug Resistance-Associated Protein 1 Is Elevated in Plasma Small Extracellular Vesicles Derived From Patients With Pancreatic Ductal Adenocarcinoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Differential Response and Resistance to KRAS-Targeted Therapy.Molecular carcinogenesis · 2025Review
- Cytosolic cytochrome c represses ferroptosis.Cell metabolism · 2025Article
- Patient-derived organoids in non-small cell lung cancer: advances in drug sensitivity testing.Frontiers in pharmacology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Xinxin SongDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-3868-2644
Zhuan ZhouDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-9683-5760
Ammar ElmezayenDepartments of Biochemistry and Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-2926-7070
Runliu WuDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-6175-8646
Chunhua YuDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-4325-6634
Boning GaoHamon Center for Therapeutic Oncology Research, Department of Pharmacology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-1382-395X
John D MinnaHamon Center for Therapeutic Oncology Research, Department of Pharmacology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-7776-0767
Kenneth D WestoverDepartments of Biochemistry and Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-3653-5923
Herbert J ZehDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-2017-1934
Guido KroemerCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.ORCID 0000-0002-9334-4405
Lynn E HeasleyDepartment of Craniofacial Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-8056-0208
Rui KangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-2725-1574
Daolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-1903-6180
Funding
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG · 2017 to 2022
$7.7MTargeting HMGB1-mediated Autophagy in Cancer TherapyR01CA160417 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2012 to 2023
$3.0MCharacterization and targeting of rapid nucleotide exchange RAS mutationsR01CA244341 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WESTOVER, KENNETH · 2020 to 2024
$1.8MMechanisms of Ferroptotic Cancer Cell DeathR01CA229275 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2019 to 2024
$1.8MThe Pancreatic Cancer MicroenvironmentR01CA211070 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KANG, RUI · 2017 to 2023
$1.4MRole of Adaptive Immunity in Lung Cancer Response to Oncogene-targeted TherapeuticsI01BX004751 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI LYNN E HEASLEY · 2019 to 2026
–BLRD VA I01 BX004751NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA160417NCI NIH HHS R01 CA211070NCI NIH HHS R01 CA229275NCI NIH HHS R01 CA244341NCI NIH HHS U54 CA224065
Abstract
Direct targeting of the
Indexed as
DasatinibDrug Resistance, NeoplasmProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)src-Family KinasesAnimalsATP-Binding Cassette, Sub-Family C ProteinsCarcinoma, Non-Small-Cell LungCell Line, TumorDrug Resistance, MultipleHumansLung NeoplasmsMiceMutationProto-Oncogene Proteins c-junXenograft Model Antitumor AssaysATP-Binding Cassette, Sub-Family C ProteinsDasatinibKRAS protein, humanmultidrug resistance-associated protein 1Protein Kinase InhibitorsProto-Oncogene Proteins c-junProto-Oncogene Proteins p21(ras)src-Family Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.